Prescribing overview
Librela is a canine biologic, not an NSAID or feline Solensia.
Key prescribing checks
- The US label contraindicates use in breeding, pregnant or lactating dogs and dogs hypersensitive to bedinvetmab; safety and effectiveness have not been evaluated below 12 months of age.
- Review the current Client Information Sheet with the owner before each injection. The 2025 labeling includes neurologic and urinary adverse-event reports, including seizures, weakness and incontinence; some reports ended in death or euthanasia. Reports alone do not establish frequency or causation.
- Safety with concurrent NSAIDs has not been established in dogs. Discuss a gradual return-to-activity plan as comfort improves and promptly investigate new clinical signs.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary approved labelOsteoarthritis-associated pain control
Not evaluated below 12 months; contraindicated in breeding, pregnant or lactating dogs.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Binds nerve growth factor, reducing NGF-mediated pain signaling.
Absorption, distribution, metabolism and elimination
Beagles: peak 4–7 days, bioavailability approximately 86%, half-life approximately 12 days; osteoarthritic dogs had variable half-life averaging 19 days.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Librela
US canine bedinvetmab injection label.
Contraindications · when not to use
- Known bedinvetmab hypersensitivity; breeding, pregnant or lactating dogs.
Precautions & monitoring
- Not evaluated below 12 months; delayed hypersensitivity is possible. Long-term cardiac effects and effects beyond nine months remain unevaluated.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Hypersensitivity is possible; postmarketing neurologic/urinary events and deaths are reported without established frequency or causality.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsOsteoarthritis painLibrela single-use injection | Minimum target 0.5 mg/kg (0.23 mg/lb) SC · Monthly Response-guided ongoing treatment | <5 kg: 0.1 mL/kg of 5 mg/mL. Label vial bands (kg→mg): 5–10→5; 10.1–20→10; 20.1–30→15; 30.1–40→20; 40.1–60→30; 60.1–80→40; 80.1–100→50; 100.1–120→60. Verify full dosing label ↗ |
Benefit may require the second dose. Concurrent NSAID safety is unestablished.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Librela
US canine bedinvetmab injection label.
- Concurrent NSAID safety is not established; other monoclonal antibody use has not been evaluated, and vaccine interactions were not assessed.
Monitoring
Review mobility, neurologic/urinary changes and continued suitability before each dose.
Client counseling
Review the Client Information Sheet before every injection; promptly report new signs.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Single-use vial: use immediately after puncture and discard remainder; follow label refrigeration requirements.
Brands, formulations & ingredient identity
Active ingredients
Bedinvetmab
Librela identifies bedinvetmab; it is not a brand synonym for feline frunevetmab (Solensia). The two species-specific antibodies must not be interchanged.
Confirm the vial strength, labeled species and prescription before preparation; a generic ingredient match does not establish an interchangeable formulation.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Librela
- Formulation
- Subcutaneous injection
- Label / product scope
- Dogs
US canine osteoarthritis-pain product; use the current prescribing information and owner sheet.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →